Interleukin-17 antagonists in the treatment of psoriasis

Journal of Cutaneous Medicine and Surgery

Volumn 19, Issue 2, 2015, Pages 109-114

  Chandrakumar, Shivani Felicia ^a   Yeung, Jensen ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BRODALUMAB; CYCLOSPORIN; ETANERCEPT; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17 RECEPTOR C; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; IXEKIZUMAB; SECUKINUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; BIOLOGICAL FACTOR;

AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CELL EXPANSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; FOLLOW UP; HUMAN; PATHOGENICITY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; TH1 CELL; TH17 CELL; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; PATHOLOGY; SKIN; TREATMENT OUTCOME;

BIOLOGICAL FACTORS; HUMANS; INTERLEUKIN-17; PSORIASIS; SKIN; TREATMENT OUTCOME;

EID: 84933035939     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2014.14038     Document Type: Review

References (27)

1. Yoo IS, Lee JH, Song ST, et al. T-helper 17 cells: the driving force of psoriasis and psoriatic arthritis. Int J Rheum Dis 2012;15:531-7, doi:10.1111/j.1756-185X.2012.01813.x.
2. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85, doi:10.1038/jid. 2012.339.
3. Mitra A, Fallen RS, Lima HC. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol 2013;44:173-82, doi:10.1007/s12016-012-8306-2.
4. Singh TP, Lee CH, Farber JM. Chemokine receptors in psoriasis. Expert Opin Ther Targets 2013;17:1405-22, doi:10.1517/14728222. 2013.838220.
5. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013;22:993-1005, doi:10.1517/13543784.2013. 806483.
6. Van den Berg WB, McInnes IB. Th17 cells and IL-17 A-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013;43:158-70, doi:10.1016/j.semarthrit.2013.04.006.
7. Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008;9:650-7, doi:10.1038/ni.1613.
8. Ortega C, Fernandez AS, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukocyte Biol 2009;86: 435-43.
9. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94, doi:10.1084/jem.20071094.
10. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124:1022-10, doi:10.1016/j.jaci.2009.08.046.
11. Mudigonda P, Mudigonda T, Feneran AN, et al. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J 2012;18:1.
12. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500, doi:10.4049/jimmunol.1100123.
13. Kuestner RE, Taft DW, Haran A, et al. Identification of IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 2013;179:5462-73, doi:10.4049/jimmunol.179.8.5462.
14. Krueger JG, Kricorian G, Aras G, et al. Brodalumab, an antiinterleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181-9, doi:10.1056/NEJMoa1109017.
15. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9, doi:10.1056/NEJMoa1109997.
16. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168:412-21, doi:10.1111/bjd.12110.
17. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimenfinding study. Br J Dermatol 2013;168:402-11, doi:10.1111/bjd.12070.
18. Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments formoderate-to-severe psoriasis:meta-Analysis of randomized controlled trials. Br J Dermatol 2014;170:274, doi:10.1111/bjd.12663.
19. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2007;366:1367-74, doi:10.1016/S0140-6736(05)67566-6.
20. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:1-15, doi:10.1016/j.jaad.2006.07.017.
21. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74, doi:10.1016/S0140-6736(08)60725-4.
22. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84, doi:10.1016/S0140-6736(08)60726-6.
23. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12, doi:10.1111/j.1365-2133.2005.06688.x.
24. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J AmAcad Dermatol 2008;58:106-15, doi:10.1016/j.jaad.2007.09.010.
25. Garber K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 2012;30:475-7, doi:10.1038/nbt0612-475.
26. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-8, doi:10.1126/science.1200439.
27. Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-Associated cytokines IL-17 and IL-22. J Invest Dermatol 2008;128: 2640-5, doi:10.1038/jid.2008.139.